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Background: Heart transplantation is limited by severe donor organ shortage. Regardless of the changes made in
the acceptance of marginal donors, any such mechanism cannot be considered successful unless recipient graft survival
rates remain acceptable. A stress echo-driven selection of donors has proven successful in older donors with normal left
ventricular resting function and in standard donors with reversible resting left ventricular dysfunction acutely improving
during stress, or slowly improving (over hours) during intensive hormonal treatment. Aim of this study is to assess the
medium-term outcome of recipients of marginal donor hearts selected with new echocardiographic techniques over
standard criteria.
Methods and results: We enrolled 43 recipients of marginal donor hearts: age > 55 years, or < 55 years but with
concomitant risk factors, n = 32; acutely improving during stress, n = 3; or slowly improving during hormonal treatment,
n = 8. At follow-up (median, 30 months; interquartile range, 21–52 months), 37 of the recipients were still alive. One-year
survival was 93%.
Conclusion: The strict use of new stress-echocardiographic techniques over standard criteria of marginal donor
management, together with comprehensive monitoring of the donor, has the potential to substantially increase
the number of donor hearts without adverse effects on recipient medium-term outcome.
Keywords: Heart transplant, Heart donor shortage, Stress echocardiography, Reversible wall motion abnormalities,
Hormonal treatmentIntroduction
Heart transplantation is an established procedure in
end-stage heart failure patients, albeit limited by severe
and incremental donor organ shortage. In Europe every
year a pool of ≈ 4500 unused hearts (500 in Italy) with
permission granted for heart donation is estimated, from
which additional transplants could be generated, with
more confidence in their post-transplantation perform-
ance (Council of Europe, Donation and Transplantation,
2011) [1,2]. A stress echo-driven selection of donors has* Correspondence: bombardini@ifc.cnr.it
1Institute of Clinical Physiology, National Research Council, Via Moruzzi 1,
56124 Pisa, Italy
Full list of author information is available at the end of the article
© 2014 Bombardini et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.proven successful in three settings: 1) older donors with
normal left ventricular (LV) resting function and negative
stress echo [3,4]; 2) reversible resting left ventricular dys-
function acutely improving over minutes during stress [5];
3) regional and global LV dysfunction slowly improving
(over hours) during intensive hormonal treatment (HT)
[6-11]. In all three conditions, encouraging results and
short-term progress have been reported in preliminary
proof of principle studies, but data on medium-term out-
come have been conspicuously lacking to date. Aim of this
study is to assess the medium-term outcome of recipients
of marginal donor hearts selected via new echocardio-
graphic techniques over standard criteria.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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According to a methodology previously described in de-
tail, in this analysis we enrolled three different categories
of potential marginal donors: 1) 97 patients enrolled in
the Adonhers project [3,4,12], consisting of potential do-
nors aged > 55 years, or < 55 years but with concomitant
risk factors; 2) 6 subjects with resting wall motion ab-
normality undergoing pharmacological stress echo [5];
3) 15 subjects with hemodynamic instability [13] Table 1.
In all cases, LV wall motion score index (WMSI) was
assessed and graded on a scale from 1 (normal) to 4
(dyskinetic) in each of the 17 segments at rest and follow-
ing intervention (pharmacological stress or HT) [14,15].
Ejection fraction was calculated using the biplane Simpson
rule [16] and LV elastance as the ratio of systolic pressure
by cuff sphygmomanometry to LV end-systolic volume
[17]. The intervention consisted of dipyridamole infu-
sion (0.84 mg/kg over 6′, n = 59) or dobutamine (up to
40 mcg/kg/min, n = 4) or – for HT – in infusion with
insulin, methylprednisolone, vasopressin and T3. Heart
eligibility criteria have been previously described in detail
[3-5,13] and are schematically summarized in Figure 1.
Briefly, in presence of normal resting function, theTable 1 Eligibility criteria in marginal donors by echocardiog
Donors aged > 55 years
with ≥ 3 risk factors
N. initially recruited 97
N. potentially eligible studied patients 57
Intervention (stress) DIP (dob)
Echo assessment following intervention Minutes
WMSI rest 1
WMSI peak 1
LVEF% rest 59 ± 10
LVEF% peak 67 ± 9
Contractile reserve +
Viability NA
Stress dismissed N = 15
Eligible non-transplanted N = 9
Eligible transplanted hearts N = 32
Donor characteristics of transplanted hearts
Age (years) 55 ± 7
Male gender 53 (58%)





Troponin > 0.14 micrograms/L 21
BSA = Body Surface Area; DIP = Dipyridamole; DOB = Dobutamine; WMSI =Wall Moteligible heart showed normal regional and global wall
motion; in presence of abnormal resting function, the
eligible heart showed regional and global wall motion
restoring over minutes with pharmacological stress or
over days with HT.
The pts in the Ht protocol were considered eligible
only after coronary angiography ruled out the presence
of coronary stenosis.Ethical committee
The ethics committee of the Emilia-Romagna and Tuscany
regions of Italy approved the Aged Donor Heart Rescue by
Stress Echo Project in 2004 (number 142/2004/U/Oss,
October 19, 2004). Partial funding for the Stress Echo
project was provided by the Italian Health Ministry
(CCM project #48, 2010). On May 11, 2011 the Italian
National Transplant Center/Italian National Institute of
Health (CNT/ISS 2011) approved the Guidelines: Increase
available organs for heart transplant with heart assessed
by stress echocardiography in older donors or in donors
with several risk factors, with a second-opinion telemedi-
cine system from the core echo lab, IFC-Pisa.raphic techniques








> 1 1/> 1
1
53 ± 8 48 ± 14




- N = 7
N = 3 N = 8
34 ± 13 50 ± 9
3 (50%) 8 (53%)






Figure 1 Donor heart eligibility criteria. Upper panel. Eligible
heart: non-inducible ischemia (first row) in hearts with normal rest
LV function; viability response at stress echo (second row) or at HT
(third row) in stunned hearts with abnormal rest LV function. Lower
panel. Non-eligible heart: stress echo positivity (first row) in hearts
with normal rest LV function, excluding the heart from transplant;
lack of viability response at stress echo (second row) or at HT (third
row) in hearts with abnormal rest LV function.
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Donors enrolled in the stress echo protocols were en-
rolled in neurological intensive care units, without direct
access to coronary angiography facilities. Standard cor-
onary angiography with IVUS was performed 1 month
after heart TX [18]. Donors enrolled in the HT protocol
underwent coronary angiography before heart harvest-
ing. Once transplanted, all patients underwent usual sur-
veillance and immunosuppression protocol and infection
prophylaxis, with serial endomyocardial biopsies accord-
ing to guidelines [19].
Statistical analysis
SPSS version 21 for Windows (SPSS, Inc., Chicago, IL,
USA) was used for statistical analyses. The statistical
analyses included descriptive statistics (frequencies and
percentages for categorical variables and mean ± SD for
continuous variables). Patient’s survival curves were esti-
mated using the Kaplan–Meier method and compared
between groups using the log-rank test. The survival
was censored at the time of death. For patients who
were still alive, survival was censored at date of last
known follow-up. Two-tailed p < 0.05 was considered
statistically significant.
Results
From April 2006 to April 2013, of the initial set of 118
enrolled subjects, 44 were deemed eligible after stress
echocardiography, and 15 after HT. Nine patients eli-
gible by stress echo were not transplanted due to: LV
hypertrophy (N = 2 cases), epicardial coronary calcium at
surgical inspection (N = 2), malignancy (N = 1), HCV
positivity (N = 1), lack of a matching recipient (N = 3).
Seven eligible donors enrolled in the HT protocol were
not transplanted due to: opposition (N = 3), tubercolosis
(N = 1), malignancy (N = 1), coronary artery stenosis atpre-harvesting angiography (N = 2); 43 marginal donor
hearts were eventually transplanted Table 2. The recipi-
ents were predominantly male (33 out of 43), with a
mean age of 56 ± 9 years. Patients were enrolled from a
waiting list: 5 recipients were United Network for Organ
Sharing (UNOS) status 1A (with mechanical circulation
support devices as bridging for HT), 7 recipients were
status 1B, and 31 were status 2 [20]. One recipient with
systemic amyloidosis received simultaneous liver Tx, one
with chronic dialysis treatment received simultaneous
kidney TX. Six recipients died at follow-up: two recipi-
ents had primary graft failure after HT, one recipient
with severe pre-TX pulmonary hypertension and one re-
cipient with previously implanted VAD as bridge to TX;
two died (at 2 months and at 18 months) from general
sepsis; one died at 32 months from allograft vasculopa-
thy [21] in recurrent multiple myeloma; one died at
16 months from newly diagnosed liver cancer. Two of
the 43 eligible transplanted hearts showed significant
(70%) stenosis of a major coronary vessel (LAD in one,
RCA in one) on 1-month post-HT coronary angiog-
raphy, and underwent PCI with stenting. At follow-up
(median, 30 months; interquartile range, 21–52 months),
37 of the recipients were still alive (Figure 2). One-year
survival was 93%. Verification by autopsy in eligible hearts
not transplanted showed absence of significant abnormal-
ities (coronary artery disease or cardiomyopathy).Discussion
This study shows that the surgical mortality rates of
adults who underwent heart transplantation of marginal
donors selected by means of new echocardiographic
techniques are excellent, and that medium-term survival
is acceptable. The most common cause of death within
1 year is graft failure, followed by infection. Notably,
only one of our patients died due to cardiac allograft
vasculopathy, in recurrent multiple myeloma. Additional
studies are needed to assess the impact of cardiac allo-
graft vasculopathy in marginal donors.Stress echocardiography to select marginal donor hearts:
strengths and weaknesses
Supply of donor hearts is a critical rate-limiting step in
heart transplantation. An effective way to solve the current
shortage would be to accept an upward shift of the age
cut-off limit and to accept for transplant normal but tem-
porarily stunned donor hearts [4,5,13,22]. Pharmacological
stress echo (with stress being classical pharmacological
stress or HT extended for several hours) can identify aged
good hearts with normal resting function (and normal re-
sponse during stress) and even with abnormal resting
function (and functional recovery during stress or follow-
ing HT) [23,24].
Table 2 Recipients of donors selected by echocardiographic techniques
Donors aged > 55 years
or with ≥ 3 risk factors




Eligible transplanted hearts N = 32 N = 3 N = 8
Cold ischemia time (minutes) 178 ± 26 161 ± 16 150 ± 19
Recipient characteristics
Age (years) 56 ± 9 53 ± 4 56 ± 7




2 23 3 5
Recipient disease
DCM 9 3
DC CHD 12 1 3
DC Valvular 2 1
HCM 4 1
Restrictive CMP in amyloidosis 3 1
DC other 2 1
TX associated to heart TX 2 (Liver N = 1, Kidney N = 1)
Survivors N 27 3 7
FOLLOW-UP, months 44 ± 24 24 ± 7 31 ± 4
Death, N 5 - 1
Deaths (cause, post TX months)
PGF 2 (2 months)
Sepsis 1 (2 months) 1 (18 months)
Cancer 1 (16 months)
Recurrent systemic myeloma 1 (32 months)
CHD = Coronary heart disease; CMP = Cardiomyopathy; DC = Dilated cardiomyopathy; DCM= Idiopathic dilated cardiomyopathy; HCM= Hypertrophic cardiomyopathy;
PGF = Primary graft failure; TX = Heart transplant.
Figure 2 Survival curves in recipients of donor hearts selected with new echocardiographic techniques. Right panel. The survival curves
of the 3 groups of pts. Left panel. The survival curve of the whole group of patients.
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butamine as the alternative, acceptable second choice.
There were two reasons for the choice: dipyridamole is
equally as accurate but technically simpler than dobuta-
mine because of a lesser increase in heart rate, and the
image quality is therefore less degraded during stress
[3,4] (this aspect is especially important in the technic-
ally challenging theater of testing potential donors who
have high resting heart rates), and further catecholamine
stress with dobutamine is in principle undesirable for
these patients, because they already have high, and poten-
tially toxic, levels of circulating catecholamines, which
may damage the heart [19,22,25].
Although appealingly simple, a stress-echo driven ap-
proach depends on the qualitative, operator-dependent as-
sessment of regional wall motion, requiring strict criteria
in the process of execution, acquisition, analysis and inter-
pretation. The Italian National Transplant Center recently
approved the stress echo methodology for selection of
older donor hearts (CNT/ISS; 2011) for all Italian regions
[25,26]. The Core Echo Lab, Pisa (IFC, National Research
Council) is responsible for accreditation of cardiologists
to carry out stress echo in each center involved in the
project, certification of a “second opinion” in near real
time, and final acceptance of the donation [12]. For
this, an Italian network of stress echo laboratories has
been organized by IFC (CNR, Pisa). All network labora-
tories have agreed to pass a quality control examination
on stress echo reading before entering the study, to
code the LV segments similarly, and to adopt a common
scoring system for wall motion analysis. The Transplant-
ation Network involves the cardiac-transplant program
throughout Italy. There are no specific requirements for
instruments and there are no additional costs for local
health agencies. In this way, at nearly no extra cost, the re-
search infrastructure allows access to donation to feed an
activity such as heart transplantation with high running
fixed costs and obvious beneficial impact on the sustain-
ability of the health system. With standard Italian health
care costs in the public system, a stress echo is priced at
around € 100, and a heart transplant (made possible by
stress echo-driven selection) around € 80,000.
Limitations of the study
In theory, it may seem more convenient to perform
stress echocardiography at the bedside rather than trans-
port the donor to the cardiac catheterization laboratory
[25-29]. The concept of replacing an invasive test requir-
ing transportation to the cardiac catheterization labora-
tory with one that could potentially be performed at the
bedside is appealing; however, the practicality of bedside
stress echocardiography requires further evaluation [25].
The decision to screen more marginal donors noninva-
sively will increase the risk for hearts with CAD beingaccepted for transplantation. The implications of this are
unclear. It has been demonstrated that the presence of
donor-transmitted coronary atherosclerosis does not ac-
celerate the progression of intimal hyperplasia or affect
the 3-year prognosis of transplant recipients. Recent
studies indicate that deleterious transplant vasculopathy
(TVP) as a result of chronic rejection is multifactorial
and that atherosclerotic plaque in the donor heart may
not necessarily progress to TVP [30-32]. Instead, using
serial Intravascular Ultrasound (IVUS) measurements, Li
et al. [33] demonstrated that pre-existing donor athero-
sclerotic lesions do not accelerate the development of
TVP either at the site of pre-existing donor atheroscler-
osis or elsewhere within the same artery. However,
donor-transmitted coronary atherosclerosis increases the
incidence of cardiac allograft vasculopathy. Recently,
Grauhan et al. [18] described an overall prevalence of
donor-transmitted coronary atherosclerosis of 7.0%, and
he stated that donor screening without coronary angio-
gram overlooks a significant proportion of coronary le-
sions. In that study, the prevalence of donor transmitted
CAD in recipients who underwent coronary angiography
within 6 months post-transplantation was 5.2%, whereas
it was 15.1% on autopsy in those recipients who died
within 6 months without coronary angiogram. Among
all patients with early graft failure, prevalence was as
high as 22.8% indicating that donor CAD represents a
significant risk factor for early graft failure [34].
Conclusions
The medium-term outcome of recipients of marginal
donor hearts selected with new echocardiographic tech-
niques over standard criteria demonstrated survival rates
similar to that of recipients of “standard” donor hearts.
As waiting lists for heart transplantation continue to
grow, continuous changes in practice patterns of donor
heart usage are most urgent. It is believed that about
15,000 patients would potentially benefit from a heart
transplant, if the acceptance criteria included ‘marginal’
donors up to 55 years of age, and about 40,000-70,000
patients would benefit, if the acceptance age was ex-
tended to 65 years [35]. In “younger marginal donors”, ag-
gressive assessment and optimal management of donor
left ventricular dysfunction offer tremendous potential
for increasing cardiac donor utilization since a signifi-
cant proportion of hearts are declined for reasons of
‘poor ventricular function’. Strong evidence indicates
that grafts from younger donors with left ventricular
dysfunction can completely recover to normal function
over time in the donor [36] and following transplant-
ation into a recipient [37]. Although echocardiography
is very effective in screening for anatomical (especially
valvular) anomalies of the heart, use of a single echo
examination in terms of a ‘snapshot assessment’ of pump
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donor graft is not well-supported by evidence [24]. How-
ever, regardless of changes in the acceptance of marginal
donors, any such mechanism will not be considered suc-
cessful unless recipient graft survival rates in center-
specific outcome analyses remain acceptable. The strict
use of new stress-echocardiographic techniques over
standard criteria of marginal donor management, together
with comprehensive monitoring of the donor, has been
shown to have the potential to increase substantially the
number of donor hearts without adverse effects on recipi-
ent medium-term outcome.
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